medigraphic.com
ISSN 1561-3070 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cub Oftal 2022; 35 (1)

Pharmacological treatment of strabismus

Pérez VM, Méndez STJ, Pérez BA, Sibello DS, Casanueva CH

Language: Spanish
References: 35
Page: 1-18
PDF size: 218.64 Kb.


ABSTRACT

Extraocular musculature surgery has been the standard of care for surgical treatment of strabismus for more than a century. Despite the great technical development of strabismus surgery today, the use of a surgical microscope, the novel design of surgical instruments, the quality of the non-absorbable suture; Advances in anesthetic equipment and drugs, it is not exempt from surgical complications, in addition to the recovery time that the patient needs to return to their social activities, have led to a permanent search for pharmacological treatment for strabismus. The objective of this bibliographic review is to analyze the different pharmacological alternatives available as a treatment for strabismus. For its preparation, full texts and articles in Spanish and English languages were consulted, available in some databases. We conclude that although numerous drugs have been studied, botulinum toxin, which is the best known and used worldwide, followed by bupivacaine. We find others such as IGF I and II (Insuline Growing Factor), capable of generating an effect of reinforcing muscle activity. And others that “weaken” MOE include mAb35-Rubicin, BMP4 (Bone Morphogenic Protein). His research is continuing today.


REFERENCES

  1. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009;54:676-82.

  2. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA. 2001;285:1059-70.

  3. Gary D. Monheit, MD; and Andy Pickett, PhD. AbobotulinumtoxinA: A 25-Year History Aesthetic Surgery Journal. 2017;37(S1):S4-S11. Disponible en: www.aestheticsurgeryjournal.com

  4. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017; 69(2):200‐235.

  5. Kumar R, Dhaliwal HP, Kukreja RV, Singh BR. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems. Semin Neurol. 2016;36(1):10‐19.

  6. Gómez de Liaño R. The Use of Botulinum Toxin in Strabismus Treatment. J Binocul Vis Ocul Motil. 2019;69(2):51‐60.

  7. Hered R. Chapter 14: Surgery for extraocular muscles. In: 2018-2019 Basic and Clinical Science Course, Section 06: Pediatric Ophthalmology and Strabismus. PA: American Academy Ophthalmology. 2018:241-242.

  8. McNeer KW, Tucker MG, Guerry CH, Spencer RF. Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J Pediatr Ophthalmol Strabismus. 2003;40:288-292.

  9. Campomanes AG de A, Binenbaum G, Eguiarte GC. Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2010;14(2):111-6.

  10. Gursoy H, Basmak H, Sahin A, Yildirim N, Aydin Y, Colak E. Long-term followup of bilateral botulinum toxin injections versus bilateral recessions of the medial rectus muscles for treatment of infantile esotropia. J AAPOS. 2012Jun;16(3):269-73. DOI: https://10.1016/j.jaapos.2012.01.010

  11. Issaho DC, Carvalho FRS, Tabuse MKU, Carrijo Carvalho LC, de Freitas D. The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-analysis. Invest Ophthalmol Vis Sci. 2017;58(12):5468-76.

  12. Wan MJ, Mantagos IS, Shah AS, Kazlas M, Hunter DG. Comparison of botulinum toxin with surgery for the treatment of acute-onset comitant Esotropia in children. Am J Ophthalmol. 2017;176:33-39. DOI: https://10.1016/j.ajo.2016.12.024

  13. Méndez Sánchez TJ, Soto Mejías MI, Pons Castro L, Naranjo Fernández RM, Casanueva Cabeza H, López Felipe Dl. Toxina botulínica versus cirugía convencional en esotropía residual. Revista Cubana de Oftalmología. 2017;30(3).

  14. Lueder GT, Galli M, Tychsen L, Yildirim C, Pegado V. Long-term results of botulinum toxin-augmented medial rectus recessions for large-angle infantile Esotropia. Am J Ophthalmol. 2012;153(3):560-563.

  15. Wan MJ, Chiu H, Shah AS, Hunter DG. Long-term surgical outcomes for largeangle infantile Esotropia. Am J Ophthalmol. 2018;189:155-159.

  16. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S92‐S100.

  17. Etezad Razavi M, Sharifi M, Armanfar F. Efficacy of botulinum toxin in the treatment of intermittent exotropia. Strabismus. 2014;22(4):176-181.

  18. Razavi ME, Sharifi M, Armanfar F. Efficacy of Botulinum Toxin in the treatment of Intermittent Exotropia. Strabismus. 2014;22(4):176-81.

  19. Sener EC, Yilmaz PT, Fatihoglu ÖU. Botulinum toxin-A injection in esotropic Duane syndrome patients up to 2 years of age. J AAPOS. 2019;23(1):25.e125.e4.

  20. Sandra Ganesh, Sasikala Elizabeth Anilkumar, and Kalpana Narendran. Botulinum toxin A in the early treatment of sixth nerve palsy in type 2 diabetes. 2019 Jul;67(7):1133-1136.

  21. Kumar S. Acute onset binocular diplopia: a retrospective observational study of 100 consecutive cases managed at a tertiary eye centre in Saudi Arabia. Eye Lond Engl. 2020 Sep;34(9):1608-1613.

  22. Iliescu DA, Timaru CM, Alexe N, Gosav E, De Simone A, Batras M, et al. Management of diplopia. Romanian J Ophthalmol. 2017 Sep 25;61(3):166-70.

  23. Rio M, Fernández L, Hernández JR. Ofalmología. Diagnóstco y tratamiento. 2nd ed. La Habana: Editorial Ciencias Médicas; 2017.

  24. Holmes JM, Liebermann L, Hatt SR, Smith SJ, Leske DA. Quantifying Diplopia with a Questionnaire. Ophthalmology. 2013;120(7):1492-6.

  25. Ruriko Oest Shirai L. Diplopía binocular por paresias o parálisis oculomotoras: resultados de las opciones de tratamiento TTR: Universidad de Ciencias Médicas de La Habana; 2020.

  26. Chen CY. Using Botulinum Toxin A as an Adjunct in the Surgery of Large-Angle Sensory Exotropia and Abducens Nerve Palsy. Semin Ophthalmol. 2019;34(78):541-2.

  27. Wong ES, Lam CP, Lau FH, Lau WW, Yam JC. Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas. Eye (Lond). 2018 Apr;32(4):768-774. DOI: https://10.1038/eye.2017.276

  28. 28 .Scott AB, Miller JM, Shieh KR. Treating strabismus by injecting the agonist muscle with bupivacaine and the antagonist with botulinum toxin. Trans Am Ophthalmol Soc. 2009; 107:104-9.

  29. Debert I, Miller JM, Danh KK, Scott AB. Pharmacologic injection treatment of comitant strabismus. J AAPOS. 2016;20(2):106-111.e2.

  30. Hopker LM, Zaupa PF, de Souza Lima Filho AA, Cronemberger MF, Tabuse MKU, Nakanami CR, et al. Bupivacaine and botulinum toxin to treat comitant strabismus. Arq Bras Oftalmol. 2012;75(2):111-5.

  31. 31 .Willoughby CL, Fleuriet J, Walton MM, Mustari MJ, McLoon LK. Adaptability of the immature ocular motor control system: unilateral IGF-1 medial rectus treatment. Invest Ophthalmol Vis Sci. 2015;56(6):3484-3496.

  32. 32 .Willoughby CL, Christiansen SP, Mustari MJ, McLoon LK. Efectos de la liberación sostenida de IGF-1 en el músculo extraocular del primate no humano infantil: adaptaciones a nivel del órgano efector. Invest Ophthalmol Vis Sci. 2012;53:68-75.

  33. Hutton JF, Rozenkov V, Khor FSL, D´Andrea JD, Lewis ID. Bone Morphogenetic Protein 4 Contributes to the Maintenance of Primitive Cord Blood Hematopoietic Progenitors in an Ex Vivo Stroma-Noncontact Co-Culture System. Stem Cells and Development. 2006;15(6):805-13.

  34. Anderson BC, Daniel ML, Kendall JD, Christiansen SP, McLoon LK. Sustained release of bone morphogenetic protein-4 in adult rabbit extraocular muscle results in decreased force and muscle size: potential for strabismus treatment. Invest Ophthalmol Vis Sci. 2011 Jun 8;52(7):4021-9.

  35. Christiansen SP, Becker BA, Iaizzo PA, McLoon LK. Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment. J AAPOS. 2003;7(1):1-6.




2020     |     www.medigraphic.com